US FDA panel votes against diabetes implant due to safety concerns
A panel of external advisors to the U.S. Food and Drug Administration voted against Intarcia Therapeutics' diabetes treatment implant on Thursday, citing risks from potential side-effects. The committee unanimously held that the benefits of the drug-device combination for the treatment of type 2 diabetes did not outweigh its risks, pointing to the need for additional safety data. The decision comes on the back of two previous rejections by the health regulator owing to the drug's potential acute kidney injury (AKI) and cardiovascular risks.